4-(piperidin-1-yl)butan-2-ol | 71648-40-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(piperidin-1-yl)butan-2-ol
• 英文别名: 4-(1-Piperidinyl)-2-butanol；4-piperidin-1-ylbutan-2-ol
• CAS: 71648-40-3
• 化学式: C₉H₁₉NO
• 分子量: 157.256
• InChiKey: ZXAPAKFRWAWSKS-UHFFFAOYSA-N

物化性质

• 沸点：
  102-103 °C(Press: 11 Torr)
• 密度：
  0.947±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(piperidin-1-yl)butan-2-ol 在 氯化亚砜 、 氯仿 作用下， 生成 (1-methyl-3-piperidino-propyl)-malonic acid diethyl ester
  参考文献：
  名称：

  Mannich; Margotte, Chemische Berichte, 1935, vol. 68, p. 278

  摘要：

  DOI：
• 作为产物：
  描述：

  哌啶 在 lithium aluminium tetrahydride 、 乙醚 、 xylene 作用下， 生成 4-(piperidin-1-yl)butan-2-ol
  参考文献：
  名称：

  Condensation of Some Trifluoromethyl Ketones with Secondary Amines and Formaldehyde

  摘要：

  DOI：

  10.1021/jo01097a014

文献信息

• A formal anti-Markovnikov hydroamination of allylic alcohols via tandem oxidation/1,4-conjugate addition/1,2-reduction using a Ru catalyst
  作者：Yushi Nakamura、Tetsuo Ohta、Yohei Oe

  DOI：10.1039/c5cc01584g

  日期：——

  A formal Ru-catalyzed anti-Markovnikov hydroamination of allylic alcohols via tandem oxidation/1,4-conjugate addition/1,2-reduction was developed.

  通过串联氧化/1,4-共轭加成/1,2-还原，开发了一种正式的Ru催化的烯丙醇反Markovnikov烯胺化反应。
• METHOD OF CAPTURING CARBON DIOXIDE FROM GAS STREAMS
  申请人：Tontiwachwuthikul Paitoon

  公开号：US20080050296A1

  公开（公告）日：2008-02-28

  The present invention relates to a method for removing carbon dioxide (CO 2 ) from a gas stream. Particularly, the present invention relates to a method for removing CO 2 from a gas stream by a liquid absorbent having an amino alcohol derived from 4-amino-2-butanol. In comparison to conventional amines, the amino alcohols of the present invention have been found to provide a higher CO 2 absorption capacity and a higher cyclic capacity for CO 2 removal.

  本发明涉及一种从气流中去除二氧化碳（CO2）的方法。特别地，本发明涉及一种使用来源于4-氨基-2-丁醇的氨基醇液体吸收剂去除气流中的 的方法。与传统胺类吸收剂相比，本发明中的氨基醇具有更高的 吸收能力和更高的 去除循环能力。
• Compounds Comprising an Oxazoline or Thiazoline Moiety, Processes for Making Them, and Their Uses
  申请人：Leurs Regorius

  公开号：US20080161331A1

  公开（公告）日：2008-07-03

  The present invention relates to compounds comprising an oxazoline or thiazoline moiety, processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as H 3 -receptor ligands, (I), wherein A 1 is CH C(CH 3 ) or N; R 1 is hydrogen or halogen; R 2 is (II); A 2 is O or S; R 3 is hydrogen, halogen, C 1-4 alkyl or C 1-4 alkoxy; R 4 is hydrogen, halogen, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethyl or —O—(CH 2 )n-NR 12a R each CH 2 in —O—(CH 2 )n-NR 12a R 12b being optionally substituted by one or two C 1-4 alkyl; R 5 is hydrogen or —O—(CH 2 ) m —NR 13a R 13b , each CH 2 in —O—(CH 2 ) m —NR 13a R 13b being optionally substituted by one or two C 1-4 alkyl, and at least one of R 4 and R 5 should be a —O—(CH 2 )n-NR 12/13a R 12/13b group.

  本发明涉及包含氧唑啉或噻唑啉基团的化合物，制备它们的方法，包含所述化合物的制药组合物以及它们作为H3受体配体的用途，其中A1为CH、C(CH3)或N；R1为氢或卤素；R2为(II)；A2为O或S；R3为氢、卤素、C1-4烷基或C1-4烷氧基；R4为氢、卤素、C1-4烷基、C1-4烷氧基、三氟甲基或-O-(CH2)n-NR12aR12b，其中-O-( )n-NR12aR12b可以选择地被一个或两个C1-4烷基取代；R5为氢或-O-( )m-NR13aR13b，每个-O-( )m-NR13aR13b中的 可以选择地被一个或两个C1-4烷基取代，并且R4和R5中至少有一个应为-O-( )n-NR12/13aR12/13b基团。
• Compounds comprising an oxazoline or thiazoline moiety, processes for making them, and their uses
  申请人：UCB Pharma, S.A.

  公开号：US07863450B2

  公开（公告）日：2011-01-04

  The present invention relates to compounds comprising an oxazoline or thiazoline moiety, processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as H3-receptor ligands, (I), wherein A1 is CH C(CH3) or N; R1 is hydrogen or halogen; R2 is (II); A2 is O or S; R3 is hydrogen, halogen, C1-4 alkyl or C1-4 alkoxy; R4 is hydrogen, halogen, C1-4 alkyl, C1-4 alkoxy, trifluoromethyl or —O—(CH2)n-NR12aR each CH2 in —O—(CH2)n-NR12aR12b being optionally substituted by one or two C1-4 alkyl; R5 is hydrogen or —O—(CH2)m—NR13aR13b, each CH2 in —O—(CH2)m—NR13aR13b being optionally substituted by one or two C1-4 alkyl, and at least one of R4 and R5 should be a —O—(CH2)n-NR12/13aR12/13b group.

  本发明涉及具有氧唑啉或噻唑啉基团的化合物，制备它们的方法，包含所述化合物的制药组合物以及其作为H3受体配体的用途，其中A1是CH、C(CH3)或N；R1是氢或卤素；R2是(II)；A2是O或S；R3是氢、卤素、C1-4烷基或C1-4烷氧基；R4是氢、卤素、C1-4烷基、C1-4烷氧基、三氟甲基或—O—(CH2)n-NR12aR，其中—O—( )n-NR12aR12b中的每个 可以选择性地由一个或两个C1-4烷基取代；R5是氢或—O—( )m—NR13aR13b，其中—O—( )m—NR13aR13b中的每个 可以选择性地由一个或两个C1-4烷基取代，且R4和R5中至少有一个应为—O—( )n-NR12/13aR12/13b基团。
• IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE
  申请人：AMBIT BIOSCIENCES CORPORATION

  公开号：US20150126505A1

  公开（公告）日：2015-05-07

  Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.

  本发明提供了用于调节受体激酶活性的化合物、组合物和方法，并用于治疗、预防或改善由受体激酶介导的一种或多种疾病或障碍的症状。